New study tests drug combo to keep bones strong after osteoporosis treatment ends
NCT ID NCT05655013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving zoledronate infusions can prevent bone loss in postmenopausal women who have stopped taking denosumab for osteoporosis. About 200 women who took denosumab for at least two years will receive zoledronate at different times. The goal is to find the best way to maintain bone density and prevent fractures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?